News & Views
Newron receives €3.7million under Italian government R&D support program
May 02 2011
Newron Pharmaceuticals SpA a research and development company focused on novel CNS and pain therapies has been advised by the Italian government’s Ministero dell’ Istruzione, dell’ Università e della Ricerca, that it is to receive a total payment of €3.7 million with immediate effect, as part of a €5 million grant for innovative R&D. In 2008 Newron was awarded the €5 million grant by the Ministry towards a €5.3 million R&D program ongoing at the company. The grant supports the research and identification of novel compounds for the treatment of diseases of the Central Nervous System. About 40% of the grant is nonreimbursable. The rest bears interest of 0.5% per year and is required to be fully repaid within 10 years from the grant date. Luca Benatti, Newron’s CEO, said: “This significant reimbursement for our R&D further strengthens our cash position and validates our continuous effort in searching for innovative Ion channel molecules for CNS diseases. This comes on the back of the private placement of SFr3.5 million (€2.7 million) completed in late December. Our operations are now funded well into 2012.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan